RT info:eu-repo/semantics/article
T1 Extracellular vesicles from human adipose-derived mesenchymal stem cells: A review of common cargos
A1 Alonso Alonso, María Luz
A1 García Posadas, Laura
A1 Diebold Luque, María Yolanda
K1 Oftalmología
K1 Extracellular vesicles
K1 Proteomic
K1 Exosome
K1 Vesículas extracelulares
K1 Proteómica
K1 Exosoma
K1 3201.09 Oftalmología
AB In recent years, the interest in adipose tissue mesenchymal cell–derived extracellular vesicles (AT-MSC-EVs) has increasingly grown. Numerous articles support the potential of human AT-MSC-EVs as a new therapeutic option for treatment of diverse diseases in the musculoskeletal and cardiovascular systems, kidney, skin, and immune system, among others. This approach makes use of the molecules transported inside of EVs, which play an important role in cell communication and in transmission of macromolecules. However, to our knowledge, there is no database where essential information about AT-MSC-EVs cargo molecules is gathered for easy reference. The aim of this study is to describe the different molecules reported so far in AT-MSC- EVs, their main molecular functions, and biological processes in which they are involved. Recently, the presence of 591 proteins and 604 microRNAs (miRNAs) has been described in human AT-MSC-EVs. The main molecular function enabled by both proteins and miRNAs present in human AT-MSC-EVs is the binding function. Signal transduction and gene silencing are the biological processes in which a greater number of proteins and miRNAs from human AT-MSC-EVs are involved, respectively. In this review we highlight the therapeutics effects of AT-MSC-EVs related with their participation in relevant biological processes including inflammation, angiogenesis, cell proliferation, apoptosis and migration, among others.
PB Springer
SN 2629-3269
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/65030
UL https://uvadoc.uva.es/handle/10324/65030
LA eng
NO Stem Cell Reviews and Reports, 2022, vol. 18, p. 854–901
NO Producción Científica
DS UVaDOC
RD 24-nov-2024